Novel oxo-rna compositions and the related applications thereof

Abstract

This invention relates to a novel modified RNA composition (called oxo-RNA) comprising at least an oxo-nucleotide (containing oxopurine) in its 3′-end region (e.g. 3′-tail, 3′-UTR). The oxo-nucleotide includes 8-hydroxyguanine/8-oxoguanine/7,8-dihydro-8-oxoguanine (or called oxo-G/oxo-dG) and 8-hydroxyadenine/8-oxoadenine (or called oxo-A/oxo-dA). Oxo-RNA can be a single-stranded RNA sequence or double-stranded duplex, or even an RNA-DNA hybrid duplex. Advantageously, this new oxo-RNA composition not only greatly enhance RNA/DNA stability and functionality but also can prevent TREX1-mediated degradation and the related non-specific immunity over-activation (e.g. cytokine storm). Most importantly, the constructs of oxo-RNA can be designed to mimic antisense RNA oligonucleotide (aRNA-ASO), small interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA) mimic, microRNA precursor (pre-miRNA), double-stranded RNA (dsRNA), RNA-DNA hybrid, long noncoding RNA (IncRNA), small activating RNA (saRNA), messenger RNA (mRNA), and/or self-amplifying RNA/mRNA (saRNA/samRNA), or a combination thereof.

Dependencies are inferred from the claim text.